Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA:688266)
China flag China · Delayed Price · Currency is CNY
79.52
-3.66 (-4.40%)
Nov 17, 2026, 3:00 PM CST

SHA:688266 Balance Sheet

Millions CNY. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
1,5842,0312,1542,110797.051,137
Trading Asset Securities
626.14-40.5137.02248.9365.26
Cash & Short-Term Investments
2,2102,0312,1942,2471,0461,202
Cash Growth
5.94%-7.43%-2.34%114.79%-12.97%-24.86%
Accounts Receivable
223.56154.25143.63101.1488.9962.37
Other Receivables
7.2610.279.3810.8912.5112.45
Receivables
230.82164.52153.01112.03101.574.82
Inventory
196.68173.27182.86110.8598.9851.91
Other Current Assets
96.2374.1345.8550.7945.377.33
Total Current Assets
2,7342,4432,5762,5201,2921,406
Property, Plant & Equipment
464.11485.89363.43271.21247.09188.91
Long-Term Investments
---5.991010
Other Intangible Assets
24.1730.5950.0169.2791.03116.29
Long-Term Deferred Charges
65.015.9811.3916.3920.9613.03
Other Long-Term Assets
20.083.633.884.027.4811.78
Total Assets
3,3072,9693,0052,8871,6681,746

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Accounts Payable
264.27244.16197.1137.73151.72118.19
Accrued Expenses
88.1589.5286.2282.0267.548.22
Short-Term Debt
548.33989.05951.86795.16390.79131.81
Current Portion of Long-Term Debt
2.6542.14.9750.5650.0430.03
Current Portion of Leases
-9.0111.213.1713.6913.55
Current Income Taxes Payable
31.3913.9720.9520.6420.2918.58
Current Unearned Revenue
94.671.25--0.280.36
Other Current Liabilities
30.8238.88101.1535.8934.8820.16
Total Current Liabilities
1,0601,4281,3731,135729.19380.89
Long-Term Debt
-8444.35-50.09-
Long-Term Leases
8.878.626.8629.4643.1848.18
Long-Term Unearned Revenue
8.718.079.211.5545.0448.05
Long-Term Deferred Tax Liabilities
-1.645.79.5813.3215.77
Other Long-Term Liabilities
510.8358.49292.4556.6--
Total Liabilities
1,5891,8891,7521,242880.82492.88

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Common Stock
264.71264.71264.71264.71240240
Additional Paid-In Capital
3,1093,1093,1203,3532,2222,205
Retained Earnings
-1,641-2,280-2,117-1,979-1,700-1,243
Comprehensive Income & Other
-14.01-14.05-14.47-5.95-2.84-6.32
Total Common Equity
1,7191,0801,2541,633759.121,196
Minority Interest
---1.2611.9828.3756.76
Shareholders' Equity
1,7191,0801,2531,645787.491,253
Total Liabilities & Equity
3,3072,9693,0052,8871,6681,746

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Total Debt
559.851,1331,039888.35547.8223.57
Net Cash (Debt)
1,650898.421,1551,358498.18978.32
Net Cash Growth
71.78%-22.21%-14.97%172.65%-49.08%-36.78%
Net Cash Per Share
6.323.424.365.312.084.08
Filing Date Shares Outstanding
264.71264.71264.71264.71264.49240
Total Common Shares Outstanding
264.71264.71264.71264.71240240
Working Capital
1,6741,0151,2021,385562.571,025
Book Value Per Share
6.494.084.746.173.164.98
Tangible Book Value
1,6951,0501,2041,564668.091,080
Tangible Book Value Per Share
6.403.974.555.912.784.50
Buildings
-138.34135.2641.9341.9341.21
Machinery
-158.18145.53120.48121.7496.02
Construction In Progress
-275.93123.47135.8386.6727.25